

18 September 2025

Our Ref: FOI 1374

Dear

**Freedom of Information Act 2000
Information in Relation to Myeloma Treatment**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above, which you requested on 22 August 2025.

A response to the questions you have raised has been provided by the Medicine, Unscheduled Care and Cancer Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

**Olivia Robinson
Information Governance Officer**

Q1. Is your health trust currently treating myeloma patients?

A1. Yes, the Trust is currently treating myeloma patients.

Q2. Please list the hospitals in your board/trust that are currently treating myeloma patients.

A2. The hospital in the Trust that is currently treating myeloma patients is the Ulster Hospital.

Q3. Please list how many myeloma patients are being treated by your board/trust. Please break this down by hospital.

A3. There are currently 135 myeloma patients that are being treated in the Ulster Hospital.

Q4. Is your health trust currently treating myeloma patients with elranatamab or teclistamab. Please break this down by hospital.

A4. Yes, the Trust is currently treating myeloma patients with elranatamab or teclistamab in the Ulster Hospital.

Q5. Please list how many people have been given a) elranatamab or b) teclistamab since approval by the National Institute of Health and Care Excellence in 2024 (TA1023 and TA1015). If possible, please break this down by hospital.

A5. Please see Table 1 for the number of patients in the Ulster Hospital that have been given the listed drugs since approval by the National Institute of Health Care and Excellence in 2024.

Table 1

Drug	Number of Patients
Elranatamab	2
Teclistamab	1

Q6. Do you have a service level agreement or referral system in place with any other health trusts to deliver a) elranatamab or b) teclistamab to patients. If the answer this question is yes, which health boards / trusts do you have an agreement in place with.

A6. The Trust does not have a service level agreement or referral system in place with any other health trusts to deliver the listed drugs to patients.